期刊文献+

新型去势难治性前列腺癌治疗药物MDV3100研究简介 被引量:4

下载PDF
导出
摘要 对于北美及欧洲的男性,除了非黑色素瘤的皮肤癌外,前列腺癌已经成为了最常见的恶性肿瘤,并且其死亡率也仅次于肺癌^[1-2]。在中国,前列腺癌的发病率也在逐年增高^[3]。对于前列腺癌患者,无论其病灶是局限型或是已出现转移病灶,抑制体内雄激素的水平长期以来一直是主要的治疗方法。
作者 王明超 程跃
出处 《现代泌尿生殖肿瘤杂志》 2013年第6期373-374,共2页 Journal of Contemporary Urologic and Reproductive Oncology
  • 相关文献

参考文献14

  • 1Jemal A,Siegel R,XU J. Cancer statistics,2010[J].{H}CA-A Cancer Journal for Clinicians,2010,(5):277-300. 被引量:1
  • 2La Vecchia C,Bosetti C,Lucchini F. Cancer mortality in Europe,2000-2004,and an overview of trends since 1975[J].{H}ANNALS OF ONCOLOGY,2010,(6):1323-1360. 被引量:1
  • 3叶定伟,李长岭.前列腺癌发病趋势的回顾和展望[J].中国癌症杂志,2007,17(3):177-180. 被引量:119
  • 4de Bono JS,Oudard S,Ozguroglu M. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment:a randomized open-label trial[J].{H}LANCET,2010,(9747):1147-1454. 被引量:1
  • 5de Bono JS,Logethetis CJ,Molina A. Abiraterone and increased survival in metastatic prostate cancer[J].{H}New England Journal of Medicine,2012,(21):1995-2005. 被引量:1
  • 6Parker C,Heinrich D,O'Sullivan JM. Overall survival benefit of radium-223 chloride (alpharadinTM) in the treatment of patients with symptomatic bone metastases in castration-resistant prostate cancer (CRPC):a phase Ⅲ rondomized trial (ALSYMPCA),in European multidsiciplinary cancer congress 2011[J].{H}EUROPEAN JOURNAL OF CANCER,2011,(Suppl 3):S4-388. 被引量:1
  • 7Kantoff PW,Higano CS,Shore ND. Sipuleucel-T immunotherapy for castration-resistant prostate cancer[J].{H}New England Journal of Medicine,2010,(5):411-422. 被引量:1
  • 8MEDIVATION. Medication and astellas announce positive survival data from interim analysis of phase 3 AFFIRM trial of MDV3100 in men with advanced prostate cancer[OL].http://cn.reuters.com/article/pressRelease/idUS109566+03-Nov-2011+MW20111103?symbol=MDVN.O,2011. 被引量:1
  • 9Tran C,Ouk S,Clegg NJ. Development of a second-generation antiandrogen for treatment of advanced prostate cancer[J].{H}SCIENCE,2009,(5928):787-790. 被引量:1
  • 10Kolvenbag GJ,Blackledge GR,Gotting-Smith K. Bicalutamide (Casodex) in the treatment of prostate cancer:history of clinical development[J].{H}PROSTATE,1998,(1):61-72. 被引量:1

二级参考文献5

共引文献118

同被引文献74

  • 1宋丽君,王飏,陆旭芳,李志裕.雄激素受体拮抗剂MDV3100的合成研究[J].精细化工中间体,2012,42(1):34-36. 被引量:7
  • 2崔福德.药剂学[M].北京:人民卫生出版社,2008:311-314. 被引量:32
  • 3TRAN C,OUK S,CLEGG N,et al. Development of a second generation antiandrogen for treatment of ad- vanced prostate cancer [J]. Science,2009,324(5928).. 787-790. 被引量:1
  • 4CHARLES kS,MICHAEL EJ,CHARLIE DC,et al. Di- arylhydantoin Compounds: US, 7709517 [ P ].2010-05-04. 被引量:1
  • 5HOWARD L SCHER,KARIM FIZAZI,FRED SAAD, et al. Increased survival with enzalutamide in prostate af- ter chemotherapy[OL]. N Engl Med: 2012-8-15. 被引量:1
  • 6FOSSA SD, SLEE PH, Brausi M, et al. Flutamide versus prednisone in patients with prostate cancer symptomati- cally progressing after androgen-ablative therapy: a phase III study of the European organization for re- search and treatment of cancer genitourinary group [J]. J Clin Oncol,2001,19(1 ) :62-71. 被引量:1
  • 7AKAZA H,HINOTSU S,USAMI M,et al. Study group for the combined androgen blockade therapy of prostate cancer combined androgen blockade with hiealutamide for advanced prostate cancer: long-term follow-up of a phase 3,double-blind,randomized study for survival [ J ]. Cancer, 2009 ; 115 ( 15 ) : 3437-3445. 被引量:1
  • 8CRAWFORI) E D,EISENBERGER M A,MCLEOD DG,et al. A controlled trial of leuprolide with and with- out flutamide in prostatic carcinoma[J]. N Engl J Med, 1989,321 (7) :419-424. 被引量:1
  • 9CHEN CD,WELSBIE DS,TRAN C,et al. Molecular determinants of resistance to antiandrogen therapy [J]. Nat Med, 2004,10( 1 ) : 33-39. 被引量:1
  • 10KOLVENBAG GJ,FURR BJ,BLACKLEDGE GR. Re- ceptor affinity and potency of non-steroidal antiandro- gens: translation of preclinical findings into clinical activity [J]. Prostate Cancer Prostatic Dis, 1998(6): 307-314. 被引量:1

引证文献4

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部